BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 P&L / Income Statement

BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Contract with Customer, Sales Channel. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

989,708,000 US dollars

Cost of sales

202,795,000 US dollars

Gross profit (calculated)

786,913,000 US dollars

Operating expenses (calculated)

675,993,000 US dollars

INCOME FROM OPERATIONS

110,920,000 US dollars

Other income (expense), net (calculated)

negative 49,536,000 US dollars

INCOME BEFORE INCOME TAXES

61,384,000 US dollars

Provision for income taxes

16,622,000 US dollars

NET INCOME

44,762,000 US dollars

Royalty and other revenues

5,315,000 US dollars

ALDURAZYME - Marketed by Sanofi

43,539,000 US dollars

Products excluding ALDURAZYME - Marketed by Company

940,854,000 US dollars

Selling, general and administrative

395,549,000 US dollars

Research and development

206,952,000 US dollars

Intangible asset amortization

73,492,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.